Trial Profile
To evaluate the real-world use of bortezomib in relapsed/refractory multiple myeloma patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.